Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples-Reference-Cited by-同舟云学术

Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples

Published:2019-06-03 Issue:1 Volume:9 Page:
ISSN:2191-219X
Container-title:EJNMMI Research
language:en
Short-container-title:EJNMMI Res

Author:

Schollhammer Romain,De Clermont Gallerande Henri,Yacoub Mokrane,Quintyn Ranty Marie-Laure,Barthe Nicole,Vimont Delphine,Hindié Elif,Fernandez Philippe,Morgat Clément

Funder

La ligue contre le Cancer de Gironde

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging

Link

http://link.springer.com/content/pdf/10.1186/s13550-019-0517-6.pdf

Reference30 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.

2. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20.

3. Eder M, Schäfer M, Bauder-Wüst U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97.

4. Morgat C, Mishra AK, Varshney R, et al. Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors. J Nucl Med. 2014;55:1650–7.

5. Schwarzenboeck SM, Rauscher I, Bluemel C, et al. PSMA ligands for PET imaging of prostate cancer. J Nucl Med. 2017;58:1545–52.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-specific membrane antigen-targeted surgery in prostate cancer: Accurate identification, real-time diagnosis, and precise resection;Theranostics;2024

2. Les radiotraceurs autres que le PSMA-ligand pour l’imagerie TEP du cancer de prostate;Médecine Nucléaire;2023-10

3. GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches;Frontiers in Oncology;2023-08-31

4. The Balance Between the Therapeutic Efficacy and Safety of [177Lu]Lu-NeoB in a Preclinical Prostate Cancer Model;Molecular Imaging and Biology;2023-08-28

5. Development of Radiopharmaceuticals for NPY Receptor-5 (Y5) Nuclear Imaging in Tumors by Synthesis of Specific Agonists and Investigation of Their Binding Mode;Bioconjugate Chemistry;2023-08-09